Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Arcadia Biosciences Inc. has a company patent portfolio with 1 pending office action. This matter is located in the Biotechnology & Pharmaceuticals technology area. The prosecution is handled within 1 distinct art unit. This indicates a highly specific area of focus for the company's current intellectual property within the biotechnology sector. The use of 1 art unit for 1 action suggests a narrow technical scope for current filings.
DEVEAU ROSEN, JASON is the busiest examiner for the portfolio, currently overseeing the 1 pending office action. This examiner is responsible for the company's entire active biotechnology prosecution. The alignment of 1 examiner and 1 art unit for 1 pending action shows a singular focus for the company's current patenting efforts. Practitioners should prioritize understanding the specific examination criteria of DEVEAU ROSEN, JASON, as this individual's review will be the sole factor in the outcome of the company's current pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEVEAU ROSEN, JASON | 1 | 80.0% | +16.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19204085 | WHEAT WITH INCREASED RESISTANT STARCH LEVELS | DEVEAU ROSEN, JASON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19204085 | WHEAT WITH INCREASED RESISTANT STARCH LEVELS | DEVEAU ROSEN, JASON | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19204085 | WHEAT WITH INCREASED RESISTANT STARCH LEVELS | DEVEAU ROSEN, JASON | 1662 | DP | Non-Final OA | — | Pending | May 09, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArcadia Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jason Deveau Rosen has the most, with 1 of Arcadia Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
